Table 2: Duration of Effect in Responders

The table for the series 1A is replaced by the following table:

The table for the series 2L is replaced by the following table:

The table for the series 4L is replaced by the following table:

Table 1 Paediatric dose to be administered once daily*

Table 1 summarizes efficacy data from this study.

The table in Article 2(4) of Regulation (EC) No 348/2000 shall be replaced by the following table:

Table 3 - Dose Modification for ALIMTA (as single agent or in combination) and Cisplatin – Neurotoxicity

Table 1: Efficacy Results from Phase III NeuroBloc Studies

the table in Section 4, paragraph 4, is replaced by the following table:

Table 1 - Dose Modification Table for ALIMTA (as single agent or in combination) AND Cisplatin – Haematologic Toxicities

the table in the Annex shall be supplemented by the table in the Annex to this Directive.

The table in Annex I is replaced by the table set out in Annex I to this Regulation.

The table in paragraph 3.7 Variable is replaced with the following table:

A tabular summary of these secondary efficacy results is presented in Table 4.

The table of item 2.1 of Chapter III, is replaced by the following table:

Table II presents minimum requirements for activities other than laboratory activities.

The table in Article 1(3) of Regulation (EC) No 2603/2000 shall be amended by adding the following:

Table 2 Paediatric dose of SUSTIVA hard capsules to be administered once daily*

On flight origin/destination table (monthly data(2))

Table 2a Dose modification guidelines for combination therapy (with ribavirin)

The table below shows the efficacy data of the 48 week analyses from the ARTEMIS trial:

Table3: Posology modifications during subsequent cycles Toxicity Haematological toxicity during a cycle

Table 1 Summary of adverse reactions in psoriasis clinical studies System Organ Class

The table in the Annex of Commission Regulation (EC) No 762/94 (9) is replaced by the following table:

Table C. - Minimum levels of taxation applicable to heating fuels and electricity

The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only.

The table in paragraph 3.5 Form of ownership or FATS identification is replaced by the following table:

The following table 2 provides the frequency of adverse drug reactions in clinical trials:

Table 2 Frequency of adverse drug reactions (ADRs) in clinical trials

Table 1 Efficacy of ZOSTAVAX Compared with Placebo in the Shingles Prevention Study

The table in Annex I to Regulation (EC) No 2505/96 is hereby replaced by the table set out in the Annex to this Regulation.

Table 1 Number of cans (incremental samples) which shall be taken to form the aggregate sample

Table 1 Progression-free survival in locally advanced disease by therapy sub-group

Table 8 Predictability of sustained response by viral response at week 12 and genotype* Treatment Ribavirin (> 10.6mg/ kg) 1

14 Table 7: Summary of efficacy analyses in the VISTA study Efficacy endpoint Time to progression –

19 Table 10 Rates of Response to retreatment in prior treatment failures

Table 3 summarises some emission concentrations and factors for wood-firing installations.

Table B. - Minimum levels of taxation applicable to motor fuels used for the purpose set out in Article 8(2)

The table in Annex I to Regulation (EC) No 2505/96 shall be replaced by the table set out in the Annex to this Regulation.

The table shall be provided within the same timescale as for the transmission of the data set out in Article 5(3) of Regulation (EC) No 1172/98.

Table 2 under point 5.1 is amended as follows: the product "spices" is added to Table 2 as follows:

Table 2 Percent of Patients Responding by Treatment Group and Phase — Cycle 1 Moderately Emetogenic Chemotherapy

18 Table 3 Effects on ACR20, Structural Joint Damage and Physical Function at week 54, ATTRACT infliximabb

Table 1 Undesirable effects in prophylactic clinical studies with premature and bronchopulmonary dysplasia paediatric populations

6 Table 1 Percent of Post-Operative Patients Responding by Treatment Group Combined Results from 2 Phase III Trials

Table 9 Summary of PASI response, PGA response and percent of patients with all nails cleared at Weeks 10, 24 and 50. EXPRESS.

The table in Section 4, paragraph 4, of Annex 1 (Common module for annual structural statistics) is replaced by the following table:

Table 3 displays adverse events which were reported at 1 year in ≥ 1 % of patients, by study treatment.

18 Table 1 Percent of Patients Receiving Highly Emetogenic Chemotherapy Responding by Treatment Group and Phase — Cycle 1